A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

A Danish team thinks it can aid rAAV manufacturers, who may not be able to spend three to five years working on a project ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The Dow, S&P 500, and Nasdaq are struggling to find a direction Wednesday as the stock market braces for minutes from the Fed's monetary policy meeting.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...